ZOLGENSMA: payments to doctors
Payments that named ZOLGENSMA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.8M
- Providers
- 386
- Transactions
- 3,911
- Average per transaction
- $465
The per-transaction average — $465 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 386 providers the average total is $4,715, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,076,624 | 59.2% |
| Avexis | $544,412 | 29.9% |
| Novartis | $149,018 | 8.2% |
| Novartis Pharma AG | $49,942 | 2.7% |